newsfilter
← Latest News
Business Wire·

Vifor Pharma reports strong H1 2021 growth, on track to meet full year guidance1

Net sales up 5.0% and EBITDA up 5.3% at constant exchange rates (CER), as patient access recovered in line with easing COVID-19 restrictions in key markets Ferinject® / Injectafer® sales up 22.8% at CER ‒ strong recovery in Q2 in line with loc